Ischemic Attack Articles & Analysis
2 news found
FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. ...
ByBayer AG
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its ...
ByBayer AG